top of page

Engineered Stem Cells Designed to Survive Without Immunosuppression in Type 1 Diabetes

Writer: Zarina Ali
Zarina Ali
Jun 27
4 min read

How Sana Biotechnology Is Reimagining the Future of Type 1 Diabetes Treatment


For more than a century, Type 1 Diabetes treatment has relied on one essential tool: insulin. While modern technologies like CGMs, insulin pumps, and automated insulin delivery systems have dramatically improved daily life, they still do not address the root cause of the disease.


Researchers are now working toward a different goal—replacing the insulin-producing cells that Type 1 Diabetes destroys.


One of the most promising approaches is stem cell–derived islet cell therapy. But while this idea has made major progress in recent years, it has faced a persistent problem from the beginning: the immune system rejects transplanted cells.

Sana Biotechnology is developing a strategy designed to overcome this barrier.



Step 1: The Challenge of Cell Replacement


The idea behind stem cell therapy is straightforward.


Scientists can grow insulin-producing islet cells in a lab and transplant them into people with Type 1 Diabetes. These cells can sense blood sugar and release insulin naturally, similar to healthy pancreatic beta cells.


In some clinical studies, these transplanted cells have helped patients reduce or even eliminate their need for insulin injections.


However, the immune system sees these cells as foreign and attacks them.


To prevent rejection, most current approaches require lifelong immunosuppressive drugs. While these drugs protect the transplanted cells, they also increase risks such as infections, kidney damage, and certain cancers.


This limitation has prevented stem cell therapies from becoming widely available.


Step 2: The Idea Behind Hypoimmune Engineering


To solve this problem, Sana Biotechnology developed a new approach called hypoimmune (HIP) engineering.


Instead of weakening the immune system, the idea is to change the transplanted cells themselves so they are harder to detect.


Think of it like this:

  • Traditional approach: suppress the immune system

  • Sana’s approach: make the transplanted cells “invisible” to immune attack


If successful, this would allow transplanted islet cells to survive inside the body without immunosuppressive medication.


This concept became the foundation for Sana’s stem cell therapy program.


Step 3: First Human Testing — UP421


Before advancing to large-scale stem cell–derived treatments, Sana tested its approach using an early proof-of-concept therapy called UP421.


UP421 uses donor-derived pancreatic islet cells that have been genetically modified using hypoimmune technology.


This was an early, small-scale human study designed primarily to evaluate safety and feasibility.


The study included a single participant with long-standing Type 1 Diabetes, and importantly, no immunosuppressive drugs were used.


After 14 months, researchers observed:

  • The transplanted cells were still surviving in the body

  • The cells continued producing insulin (measured through C-peptide levels)

  • The cells responded to meals by releasing insulin

  • There was no clear evidence of immune rejection

  • No major safety issues related to the therapy were reported


While this was only one participant, it provided the first human evidence that engineered islet cells might survive without being attacked by the immune system.


Step 4: The Next Generation Therapy — SC451


Building on these early results, Sana’s next step is a therapy called SC451.


SC451 represents a major advancement because it combines two technologies:

  • Stem cell–derived islet cells (which can be produced at scale in a lab)

  • Hypoimmune genetic engineering (to protect those cells from immune rejection)


The goal of SC451 is simple but powerful:

Create an unlimited supply of insulin-producing cells that can survive in the body without immunosuppressive drugs.


If successful, SC451 could become a one-time treatment that restores natural insulin production in people with Type 1 Diabetes.


However, SC451 is still in early clinical development and has not yet been tested in large human trials.


Step 5: Moving Toward Clinical Trials — Mayo Clinic Partnership


To help move SC451 from experimental science to real-world treatment, Sana Biotechnology partnered with Mayo Clinic in April 2026.


Mayo Clinic is one of the world’s leading centers for diabetes care and transplantation research, making it an important partner for testing and refining new therapies.


Together, Sana and Mayo Clinic are working on:

  • Preparing SC451 for clinical use in humans

  • Improving transplant procedures and patient care protocols

  • Designing future clinical trials

  • Identifying biomarkers to measure how well the therapy works


Mayo Clinic also made an equity investment in Sana Biotechnology, signaling strong confidence in the potential of this research.


This partnership is a key step in moving SC451 from laboratory development toward clinical reality.


Why This Matters


The story of Sana Biotechnology reflects a major shift in Type 1 Diabetes research.


Early efforts focused on managing blood sugar. More recent advances have focused on replacing insulin-producing cells. Now, the next challenge is clear: making those cells survive long term inside the body.


Sana’s approach is important because it directly targets the immune system barrier that has limited previous stem cell therapies.


If future clinical trials confirm that hypoimmune-engineered cells can survive safely and function long term, this could significantly expand access to cell replacement therapies and reduce reliance on lifelong insulin injections.


It is still early, and SC451 is not yet an approved treatment. But the progression from UP421 to SC451 represents one of the most promising directions in modern Type 1 Diabetes research.


Research in 60 Seconds


Breakthrough: Hypoimmune-engineered stem cell–derived islet cells


Company: Sana Biotechnology


Clinical Partner: Mayo Clinic


Timeline:

  • UP421: Early proof-of-concept donor cell study

  • SC451: Next-generation stem cell therapy in development


Goal: Restore insulin production without insulin injections or immunosuppressive drugs


Current Stage: Early clinical development


Why It Matters: This approach tackles one of the biggest barriers in stem cell therapy—immune rejection—by making transplanted cells invisible to the immune system


Important Context: This is still experimental research. Larger clinical trials are needed before it can become an approved treatment

 
 
 

Comments


bottom of page